¹û¶³´«Ã½ Researchers Pioneering Ethical AI-Driven Nanomedicine for Brain Disorders
¹û¶³´«Ã½ researchers, led by Philip Nickel, are pioneering ethical AI-driven nanomedicine in the €7.8 million NAP4DIVE project to reduce animal use in drug development
The Philosophy & Ethics group of the department of Industrial Engineering & Innovation Sciences is participating in the NAP4DIVE research program, led by Finland's Åbo Akademi. This Horizon Europe project, with total funding of €7.8 million, focuses on developing AI models that identify the most efficient nanomedicine designs to treat brain diseases.
Fewer laboratory animals
Philip Nickel is leading the ethical analysis within the NAP4DIVE project, aiming to reduce the use of animals in drug development. By integrating ethical guidelines into AI-driven nanomedicine research, the project seeks to provide innovative and humane solutions for treating brain diseases. The NAP4DIVE initiative combines AI models with organ-on-a-chip technology to predict and test promising nanomolecules. This approach not only aligns with strong public support in Europe for reducing animal testing but also leverages Nickel's expertise in research ethics governance and trustworthy AI. The ultimate goal is to achieve translational medicine that minimizes reliance on animals before clinical research.
Nano medicine
This research not only offers hope for more effective treatments for brain diseases, but also contributes to ethical advances in medical science. A concrete example is the development of nanoparticles specifically aimed at delivering drugs to the brain, which could significantly improve the effectiveness of treatments without relying on animal testing.